Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells

Human mesenchymal stromal/stem cells (hMSCs) are used in experimental cell therapy to treat various immunological disorders, and the extracellular vesicles (hMSC-EVs) they produce have emerged as an option for cell-free therapeutics. The immunomodulatory function of hMSCs resembles the resolution of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochimica et biophysica acta. Molecular and cell biology of lipids 2019-10, Vol.1864 (10), p.1350-1362
Hauptverfasser: Holopainen, Minna, Colas, Romain A., Valkonen, Sami, Tigistu-Sahle, Feven, Hyvärinen, Kati, Mazzacuva, Francesca, Lehenkari, Petri, Käkelä, Reijo, Dalli, Jesmond, Kerkelä, Erja, Laitinen, Saara
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1362
container_issue 10
container_start_page 1350
container_title Biochimica et biophysica acta. Molecular and cell biology of lipids
container_volume 1864
creator Holopainen, Minna
Colas, Romain A.
Valkonen, Sami
Tigistu-Sahle, Feven
Hyvärinen, Kati
Mazzacuva, Francesca
Lehenkari, Petri
Käkelä, Reijo
Dalli, Jesmond
Kerkelä, Erja
Laitinen, Saara
description Human mesenchymal stromal/stem cells (hMSCs) are used in experimental cell therapy to treat various immunological disorders, and the extracellular vesicles (hMSC-EVs) they produce have emerged as an option for cell-free therapeutics. The immunomodulatory function of hMSCs resembles the resolution of inflammation, in which proresolving lipid mediators (LMs) play key roles. Multiple mechanisms underlying the hMSC immunosuppressive effect has been elucidated; however, the impact of LMs and EVs in the resolution is poorly understood. In this study, we supplemented hMSCs with polyunsaturated fatty acids (PUFAs); arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid, which serve as precursors for multiple LMs. We then determined the consequent compositional modifications in the fatty acid, phospholipid, and LM profiles. Mass spectrometric analyses revealed that the supplemented PUFAs were incorporated into the main membrane phospholipid classes with different dynamics, with phosphatidylcholine serving as the first acceptor. Most importantly, the PUFA modifications were transferred into hMSC-EVs, which are known to mediate hMSC immunomodulation. Furthermore, the membrane-incorporated PUFAs influenced the LM profile by increasing the production of downstream prostaglandin E2 and proresolving LMs, including Resolvin E2 and Resolvin D6. The production of LMs was further enhanced by a highly proinflammatory stimulus, which resulted in an increase in a number of mediators, most notably prostaglandins, while other stimulatory conditions had less a pronounced impact after a 48-h incubation. The current findings suggest that PUFA manipulations of hMSCs exert significant immunomodulatory effects via EVs and proresolving LMs, the composition of which can be modified to potentiate the therapeutic impact of hMSCs. •Cell membrane phospholipids of hBMSCs accept supplemented PUFAs with different dynamics.•Extracellular vesicle membranes of hBMSCs can be modified with PUFA supplementation.•hBMSCs produce proresolving lipid mediators.•PUFA supplementation and inflammatory stimuli impact the lipid mediator profile.
doi_str_mv 10.1016/j.bbalip.2019.06.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242817039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1388198119301131</els_id><sourcerecordid>2242817039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-ff21f916ed6ff4dc107296644c6b39d4b3a0135b39c90c7b87c7dd7dea7c13d13</originalsourceid><addsrcrecordid>eNp9UU1v1DAQjRAVLYV_gJCPXBI8cdZJLkioKh9SJXpoz5Zjj1mvknjxOCvyg_ifOGzhyGnG9nt-b-YVxRvgFXCQ7w_VMOjRH6uaQ19xWXHgz4or6Nq-rCV0z3Mvuq6EvoPL4iXRgXPYCbF7UVwKqHkrdvKq-HUfxnWZSacl6oSWOZ3SyrTxltgUrHcrS3tk-DNFbXAcl1FHdkLyZkQ24TREPSMxPVvmZxNRE_4hHGOwi0k-zCy47RSRwnjy83eWTXubudbrFCJt7_tl0nO-IpzNfp30yCjFsNVNk14VF06PhK-f6nXx-On24eZLefft89ebj3elaXiXSudqcD1ItNK5xhrgbd1L2TRGDqK3zSA0B7HLvem5aYeuNa21rUXdGhAWxHXx7vxv9vtjQUpq8rQ5yDOGhVRdN3UHLRd9hjZnqImBKKJTx-gnHVcFXG0BqYM6B6S2gBSXKgeUaW-fFJYhb-Af6W8iGfDhDMA858ljVGR83kreVkSTlA3-_wq_AS1CqQ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242817039</pqid></control><display><type>article</type><title>Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Holopainen, Minna ; Colas, Romain A. ; Valkonen, Sami ; Tigistu-Sahle, Feven ; Hyvärinen, Kati ; Mazzacuva, Francesca ; Lehenkari, Petri ; Käkelä, Reijo ; Dalli, Jesmond ; Kerkelä, Erja ; Laitinen, Saara</creator><creatorcontrib>Holopainen, Minna ; Colas, Romain A. ; Valkonen, Sami ; Tigistu-Sahle, Feven ; Hyvärinen, Kati ; Mazzacuva, Francesca ; Lehenkari, Petri ; Käkelä, Reijo ; Dalli, Jesmond ; Kerkelä, Erja ; Laitinen, Saara</creatorcontrib><description>Human mesenchymal stromal/stem cells (hMSCs) are used in experimental cell therapy to treat various immunological disorders, and the extracellular vesicles (hMSC-EVs) they produce have emerged as an option for cell-free therapeutics. The immunomodulatory function of hMSCs resembles the resolution of inflammation, in which proresolving lipid mediators (LMs) play key roles. Multiple mechanisms underlying the hMSC immunosuppressive effect has been elucidated; however, the impact of LMs and EVs in the resolution is poorly understood. In this study, we supplemented hMSCs with polyunsaturated fatty acids (PUFAs); arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid, which serve as precursors for multiple LMs. We then determined the consequent compositional modifications in the fatty acid, phospholipid, and LM profiles. Mass spectrometric analyses revealed that the supplemented PUFAs were incorporated into the main membrane phospholipid classes with different dynamics, with phosphatidylcholine serving as the first acceptor. Most importantly, the PUFA modifications were transferred into hMSC-EVs, which are known to mediate hMSC immunomodulation. Furthermore, the membrane-incorporated PUFAs influenced the LM profile by increasing the production of downstream prostaglandin E2 and proresolving LMs, including Resolvin E2 and Resolvin D6. The production of LMs was further enhanced by a highly proinflammatory stimulus, which resulted in an increase in a number of mediators, most notably prostaglandins, while other stimulatory conditions had less a pronounced impact after a 48-h incubation. The current findings suggest that PUFA manipulations of hMSCs exert significant immunomodulatory effects via EVs and proresolving LMs, the composition of which can be modified to potentiate the therapeutic impact of hMSCs. •Cell membrane phospholipids of hBMSCs accept supplemented PUFAs with different dynamics.•Extracellular vesicle membranes of hBMSCs can be modified with PUFA supplementation.•hBMSCs produce proresolving lipid mediators.•PUFA supplementation and inflammatory stimuli impact the lipid mediator profile.</description><identifier>ISSN: 1388-1981</identifier><identifier>EISSN: 1879-2618</identifier><identifier>DOI: 10.1016/j.bbalip.2019.06.010</identifier><identifier>PMID: 31207356</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cell therapy ; Cells, Cultured ; Dinoprostone - metabolism ; Extracellular Vesicles - metabolism ; Fatty Acids - metabolism ; Fatty Acids, Unsaturated - metabolism ; Humans ; Inflammation Mediators - metabolism ; Mesenchymal Stem Cells - metabolism ; Phospholipid ; Phospholipids - metabolism ; Prostaglandin E2 ; Specialized proresolving mediator</subject><ispartof>Biochimica et biophysica acta. Molecular and cell biology of lipids, 2019-10, Vol.1864 (10), p.1350-1362</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-ff21f916ed6ff4dc107296644c6b39d4b3a0135b39c90c7b87c7dd7dea7c13d13</citedby><cites>FETCH-LOGICAL-c408t-ff21f916ed6ff4dc107296644c6b39d4b3a0135b39c90c7b87c7dd7dea7c13d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbalip.2019.06.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31207356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holopainen, Minna</creatorcontrib><creatorcontrib>Colas, Romain A.</creatorcontrib><creatorcontrib>Valkonen, Sami</creatorcontrib><creatorcontrib>Tigistu-Sahle, Feven</creatorcontrib><creatorcontrib>Hyvärinen, Kati</creatorcontrib><creatorcontrib>Mazzacuva, Francesca</creatorcontrib><creatorcontrib>Lehenkari, Petri</creatorcontrib><creatorcontrib>Käkelä, Reijo</creatorcontrib><creatorcontrib>Dalli, Jesmond</creatorcontrib><creatorcontrib>Kerkelä, Erja</creatorcontrib><creatorcontrib>Laitinen, Saara</creatorcontrib><title>Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells</title><title>Biochimica et biophysica acta. Molecular and cell biology of lipids</title><addtitle>Biochim Biophys Acta Mol Cell Biol Lipids</addtitle><description>Human mesenchymal stromal/stem cells (hMSCs) are used in experimental cell therapy to treat various immunological disorders, and the extracellular vesicles (hMSC-EVs) they produce have emerged as an option for cell-free therapeutics. The immunomodulatory function of hMSCs resembles the resolution of inflammation, in which proresolving lipid mediators (LMs) play key roles. Multiple mechanisms underlying the hMSC immunosuppressive effect has been elucidated; however, the impact of LMs and EVs in the resolution is poorly understood. In this study, we supplemented hMSCs with polyunsaturated fatty acids (PUFAs); arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid, which serve as precursors for multiple LMs. We then determined the consequent compositional modifications in the fatty acid, phospholipid, and LM profiles. Mass spectrometric analyses revealed that the supplemented PUFAs were incorporated into the main membrane phospholipid classes with different dynamics, with phosphatidylcholine serving as the first acceptor. Most importantly, the PUFA modifications were transferred into hMSC-EVs, which are known to mediate hMSC immunomodulation. Furthermore, the membrane-incorporated PUFAs influenced the LM profile by increasing the production of downstream prostaglandin E2 and proresolving LMs, including Resolvin E2 and Resolvin D6. The production of LMs was further enhanced by a highly proinflammatory stimulus, which resulted in an increase in a number of mediators, most notably prostaglandins, while other stimulatory conditions had less a pronounced impact after a 48-h incubation. The current findings suggest that PUFA manipulations of hMSCs exert significant immunomodulatory effects via EVs and proresolving LMs, the composition of which can be modified to potentiate the therapeutic impact of hMSCs. •Cell membrane phospholipids of hBMSCs accept supplemented PUFAs with different dynamics.•Extracellular vesicle membranes of hBMSCs can be modified with PUFA supplementation.•hBMSCs produce proresolving lipid mediators.•PUFA supplementation and inflammatory stimuli impact the lipid mediator profile.</description><subject>Cell therapy</subject><subject>Cells, Cultured</subject><subject>Dinoprostone - metabolism</subject><subject>Extracellular Vesicles - metabolism</subject><subject>Fatty Acids - metabolism</subject><subject>Fatty Acids, Unsaturated - metabolism</subject><subject>Humans</subject><subject>Inflammation Mediators - metabolism</subject><subject>Mesenchymal Stem Cells - metabolism</subject><subject>Phospholipid</subject><subject>Phospholipids - metabolism</subject><subject>Prostaglandin E2</subject><subject>Specialized proresolving mediator</subject><issn>1388-1981</issn><issn>1879-2618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1DAQjRAVLYV_gJCPXBI8cdZJLkioKh9SJXpoz5Zjj1mvknjxOCvyg_ifOGzhyGnG9nt-b-YVxRvgFXCQ7w_VMOjRH6uaQ19xWXHgz4or6Nq-rCV0z3Mvuq6EvoPL4iXRgXPYCbF7UVwKqHkrdvKq-HUfxnWZSacl6oSWOZ3SyrTxltgUrHcrS3tk-DNFbXAcl1FHdkLyZkQ24TREPSMxPVvmZxNRE_4hHGOwi0k-zCy47RSRwnjy83eWTXubudbrFCJt7_tl0nO-IpzNfp30yCjFsNVNk14VF06PhK-f6nXx-On24eZLefft89ebj3elaXiXSudqcD1ItNK5xhrgbd1L2TRGDqK3zSA0B7HLvem5aYeuNa21rUXdGhAWxHXx7vxv9vtjQUpq8rQ5yDOGhVRdN3UHLRd9hjZnqImBKKJTx-gnHVcFXG0BqYM6B6S2gBSXKgeUaW-fFJYhb-Af6W8iGfDhDMA858ljVGR83kreVkSTlA3-_wq_AS1CqQ4</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Holopainen, Minna</creator><creator>Colas, Romain A.</creator><creator>Valkonen, Sami</creator><creator>Tigistu-Sahle, Feven</creator><creator>Hyvärinen, Kati</creator><creator>Mazzacuva, Francesca</creator><creator>Lehenkari, Petri</creator><creator>Käkelä, Reijo</creator><creator>Dalli, Jesmond</creator><creator>Kerkelä, Erja</creator><creator>Laitinen, Saara</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201910</creationdate><title>Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells</title><author>Holopainen, Minna ; Colas, Romain A. ; Valkonen, Sami ; Tigistu-Sahle, Feven ; Hyvärinen, Kati ; Mazzacuva, Francesca ; Lehenkari, Petri ; Käkelä, Reijo ; Dalli, Jesmond ; Kerkelä, Erja ; Laitinen, Saara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-ff21f916ed6ff4dc107296644c6b39d4b3a0135b39c90c7b87c7dd7dea7c13d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cell therapy</topic><topic>Cells, Cultured</topic><topic>Dinoprostone - metabolism</topic><topic>Extracellular Vesicles - metabolism</topic><topic>Fatty Acids - metabolism</topic><topic>Fatty Acids, Unsaturated - metabolism</topic><topic>Humans</topic><topic>Inflammation Mediators - metabolism</topic><topic>Mesenchymal Stem Cells - metabolism</topic><topic>Phospholipid</topic><topic>Phospholipids - metabolism</topic><topic>Prostaglandin E2</topic><topic>Specialized proresolving mediator</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holopainen, Minna</creatorcontrib><creatorcontrib>Colas, Romain A.</creatorcontrib><creatorcontrib>Valkonen, Sami</creatorcontrib><creatorcontrib>Tigistu-Sahle, Feven</creatorcontrib><creatorcontrib>Hyvärinen, Kati</creatorcontrib><creatorcontrib>Mazzacuva, Francesca</creatorcontrib><creatorcontrib>Lehenkari, Petri</creatorcontrib><creatorcontrib>Käkelä, Reijo</creatorcontrib><creatorcontrib>Dalli, Jesmond</creatorcontrib><creatorcontrib>Kerkelä, Erja</creatorcontrib><creatorcontrib>Laitinen, Saara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochimica et biophysica acta. Molecular and cell biology of lipids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holopainen, Minna</au><au>Colas, Romain A.</au><au>Valkonen, Sami</au><au>Tigistu-Sahle, Feven</au><au>Hyvärinen, Kati</au><au>Mazzacuva, Francesca</au><au>Lehenkari, Petri</au><au>Käkelä, Reijo</au><au>Dalli, Jesmond</au><au>Kerkelä, Erja</au><au>Laitinen, Saara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells</atitle><jtitle>Biochimica et biophysica acta. Molecular and cell biology of lipids</jtitle><addtitle>Biochim Biophys Acta Mol Cell Biol Lipids</addtitle><date>2019-10</date><risdate>2019</risdate><volume>1864</volume><issue>10</issue><spage>1350</spage><epage>1362</epage><pages>1350-1362</pages><issn>1388-1981</issn><eissn>1879-2618</eissn><abstract>Human mesenchymal stromal/stem cells (hMSCs) are used in experimental cell therapy to treat various immunological disorders, and the extracellular vesicles (hMSC-EVs) they produce have emerged as an option for cell-free therapeutics. The immunomodulatory function of hMSCs resembles the resolution of inflammation, in which proresolving lipid mediators (LMs) play key roles. Multiple mechanisms underlying the hMSC immunosuppressive effect has been elucidated; however, the impact of LMs and EVs in the resolution is poorly understood. In this study, we supplemented hMSCs with polyunsaturated fatty acids (PUFAs); arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid, which serve as precursors for multiple LMs. We then determined the consequent compositional modifications in the fatty acid, phospholipid, and LM profiles. Mass spectrometric analyses revealed that the supplemented PUFAs were incorporated into the main membrane phospholipid classes with different dynamics, with phosphatidylcholine serving as the first acceptor. Most importantly, the PUFA modifications were transferred into hMSC-EVs, which are known to mediate hMSC immunomodulation. Furthermore, the membrane-incorporated PUFAs influenced the LM profile by increasing the production of downstream prostaglandin E2 and proresolving LMs, including Resolvin E2 and Resolvin D6. The production of LMs was further enhanced by a highly proinflammatory stimulus, which resulted in an increase in a number of mediators, most notably prostaglandins, while other stimulatory conditions had less a pronounced impact after a 48-h incubation. The current findings suggest that PUFA manipulations of hMSCs exert significant immunomodulatory effects via EVs and proresolving LMs, the composition of which can be modified to potentiate the therapeutic impact of hMSCs. •Cell membrane phospholipids of hBMSCs accept supplemented PUFAs with different dynamics.•Extracellular vesicle membranes of hBMSCs can be modified with PUFA supplementation.•hBMSCs produce proresolving lipid mediators.•PUFA supplementation and inflammatory stimuli impact the lipid mediator profile.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31207356</pmid><doi>10.1016/j.bbalip.2019.06.010</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1388-1981
ispartof Biochimica et biophysica acta. Molecular and cell biology of lipids, 2019-10, Vol.1864 (10), p.1350-1362
issn 1388-1981
1879-2618
language eng
recordid cdi_proquest_miscellaneous_2242817039
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Cell therapy
Cells, Cultured
Dinoprostone - metabolism
Extracellular Vesicles - metabolism
Fatty Acids - metabolism
Fatty Acids, Unsaturated - metabolism
Humans
Inflammation Mediators - metabolism
Mesenchymal Stem Cells - metabolism
Phospholipid
Phospholipids - metabolism
Prostaglandin E2
Specialized proresolving mediator
title Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A11%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Polyunsaturated%20fatty%20acids%20modify%20the%20extracellular%20vesicle%20membranes%20and%20increase%20the%20production%20of%20proresolving%20lipid%20mediators%20of%20human%20mesenchymal%20stromal%20cells&rft.jtitle=Biochimica%20et%20biophysica%20acta.%20Molecular%20and%20cell%20biology%20of%20lipids&rft.au=Holopainen,%20Minna&rft.date=2019-10&rft.volume=1864&rft.issue=10&rft.spage=1350&rft.epage=1362&rft.pages=1350-1362&rft.issn=1388-1981&rft.eissn=1879-2618&rft_id=info:doi/10.1016/j.bbalip.2019.06.010&rft_dat=%3Cproquest_cross%3E2242817039%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242817039&rft_id=info:pmid/31207356&rft_els_id=S1388198119301131&rfr_iscdi=true